Is phage therapy acceptable in the immunocompromised host?

International Journal of Infectious Diseases

Volumn 12, Issue 5, 2008, Pages 466-471

  Borysowski, Jan ^a   Górski, Andrzej ^a,b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Antibiotic resistance; Bacteriophage; Immunocompromised host; Immunodeficiency; Phage therapy

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIOPHAGE; DRUG HALF LIFE; DRUG SAFETY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE STATUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PATIENT SAFETY; RISK ASSESSMENT; SHORT SURVEY; STAPHYLOCOCCUS INFECTION; TREATMENT INDICATION; TREATMENT RESPONSE;

BACTERIAL INFECTIONS; BACTERIOLYSIS; BACTERIOPHAGES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; IMMUNOCOMPROMISED HOST; LYSOGENY;

EID: 50249163943     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2008.01.006     Document Type: Short Survey

References (57)

1. Giamarellou H. Treatment options for multidrug-resistant bacteria. Fut Drugs 4 (2006) 601-618
2. Livermore D.H. The need for new antibiotics. Clin Microbiol Infect 10 Suppl 4 (2004) 1-9
3. Powers J.H. Antimicrobial drug development-the past, the present, and the future. Clin Microbiol Infect 10 Suppl 4 (2004) 23-31
4. Breithaupt H. The new antibiotics. Nat Biotechnol 17 (1999) 1165-1169
5. Hanlon G.W. Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Int J Antimicrob Agents 30 (2007) 118-128
6. Merril C., Scholl D., and Adhya S.L. The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Disc 2 (2003) 489-497
7. Matsuzaki S., Yasuda M., Nishikawa H., Kuroda M., Ujihara T., Shuin T., et al. Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. J Infect Dis 187 (2003) 613-624
8. Capparelli R., Parlato M., Borriello G., Salvatore P., and Iannelli D. Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother 51 (2007) 2765-2773
9. Wang J., Hu B., Xu M., Yan O., Liu S., Zhu X., et al. Use of bacteriophage in the treatment of experimental bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int J Mol Med 17 (2006) 309-317
10. Sulakvelidze A., Alavidze Z., and Morris J.G. Bacteriophage therapy. Antimicrob Agents Chemother 45 (2001) 649-659
11. Alisky J., Iczkowski K., Rapoport A., and Troitsky N. Bacteriophages show promise as antimicrobial agents. J Infect 36 (1998) 5-15
12. Sulakvelidze A., and Kutter E. Phage therapy in humans. In: Kutter E., and Sulakvelidze A. (Eds). Bacteriophages: biology and applications (2005), CRC Press, Boca Raton 381-436
13. Bearden C.M., Agarwal A., Book B.K., Vieira C.A., Sidner R.A., Ochs H.D., et al. Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transpl 5 (2005) 50-57
14. Gorski A., Borysowski J., Miedzybrodzki R., and Weber-Dabrowska B. Bacteriophages in medicine. In: McGrath S., and van Sinderen D. (Eds). Bacteriophage: genetics and molecular biology (2007), Caister Academic Press, Norfolk 125-158
15. Fishman J.A., and Rubin R.H. Infection in organ-transplant recipients. N Engl J Med 338 (1998) 1741-1751
16. Schmaldienst S., and Horl W.H. Bacterial infections after renal transplantation. Nephron 75 (1997) 140-153
17. Dharnidharka V.R., Caillard S., Agodoa L.Y., and Abbott K.C. Infection frequency and profile in different age groups of kidney transplant recipients. Transplantation 81 (2006) 1662-1667
18. Multiply antibiotic-resistant Gram-negative bacteria. Am J Transpl 2004;4 (Suppl 10):21-4.
19. Multiply resistant Gram-positive bacteria. Am J Transpl 2004;4 (Suppl 10):31-6.
20. Blair J.E., and Kusne S. Bacterial, mycobacterial, and protozoa infections after liver transplantation-Part I. Liver Transpl 11 (2005) 1452-1459
21. Zinner S.H. New pathogens in neutropenic patients with cancer: an update for the new millennium. Int J Antimicrob Agents 16 (2000) 97-101
22. Neuburger S., and Maschmeyer G. Update on management of infections in cancer and stem cell transplant patients. Ann Hematol 85 (2006) 345-356
23. Carneiro-Sampaio M., and Coutinho A. Immunity to microbes: lessons from primary immunodeficiencies. Infect Immun 75 (2007) 1545-1555
24. Nagappan V., and Kazanjian P. Bacterial infections in adult HIV-infected patients. HIV Clin Trials 6 (2005) 213-228
25. Noursadeghi M., Katz D.R., and Miller R.F. HIV-1 infection of mononuclear phagocytic cells: the case for bacterial innate immune deficiency in AIDS. Lancet Infect Dis 6 (2006) 794-804
26. Smith H.W., and Huggins M.B. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol 128 (1982) 307-318
27. Campbell A. The future of bacteriophage biology. Nat Rev Genet 4 (2003) 471-477
28. Wang J., Hu B., Xu M., Yan O., Liu S., Zhu X., et al. Therapeutic effectiveness of bacteriophages in the rescue of mice with extended-spectrum beta-lactamase-producing Escherichia coli bacteremia. Int J Mol Med 17 (2006) 347-355
29. Biswas B., Adhya S., Washart P., Paul B., Trostel A.N., Powell B., et al. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun 70 (2002) 204-210
30. Carlton R.M., Noordman W.H., Biswas B., de Meester E.D., and Loessner M.J. Bacteriophage P100 for control of Listeria monocytogenes in foods: genome sequence, bioinformatic analyses, oral toxicity study, and application. Regul Toxicol Pharmacol 43 (2005) 301-312
31. Skurnik M., Pajunen M., and Kiljunen S. Biotechnological challenges of phage therapy. Biotechnol Lett 29 (2007) 995-1003
32. Weber-Dabrowska B., Mulczyk M., and Gorski A. Bacteriophage therapy of bacterial infections: an update of our institute's experience. Arch Immunol Ther Exp 48 (2000) 547-551
33. Thiel K. Old dogma, new tricks. Nat Biotechnol 22 (2004) 31-36
34. Hausler T. Bug killers. Nat Med 12 (2006) 600-601
35. Bruttin A., and Brussow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother 49 (2005) 2874-2878
36. Miedzybrodzki R., Fortuna W., Weber-Dabrowska B., and Gorski A. Phage therapy of staphylococcal infections (including MRSA) may be less expensive than antibiotic treatment. Postepy Hig Med Dosw 61 (2007) 461-465
37. Boratynski J., Syper D., Weber-Dabrowska B., Lusiak-Szelachowska M., Pozniak G., and Gorski A. Preparation of endotoxin-free bacteriophages. Cell Mol Biol Lett 9 (2004) 253-259
38. Pirofski L.A., and Casadevall A. Use of licensed vaccines for active immunization of the immunocompromised host. Clin Microbiol Rev 11 (1998) 1-26
39. Levin B.R., and Bull J.J. Population and evolutionary dynamics of phage therapy. Nat Rev Microbiol 2 (2004) 166-173
40. Geier M.R., Trigg M.E., and Merril C.R. Fate of bacteriophage lambda in non-immune germ-free mice. Nature 246 (1973) 221-223
41. Srivastava A.S., Kaido T., and Carrier E. Immunological factors that affect the in vivo fate of T7 phage in the mouse. J Virol Methods 115 (2004) 99-104
42. Kochetkova V.A., Mamontov A.S., Moskovtseva R.L., Erastova E.I., Trofimov E.I., Popov M.I., et al. Phagotherapy of postoperative suppurative-inflammatory complications in patients with neoplasms [article in Russian]. Sov Med 6 (1989) 23-26
43. Tolkacheva T.V., Abakumov E.M., Martynova V.A., and Golosova T.V. Correction of intestinal dysbacteriosis with biological preparations in acute leukemia [article in Russian]. Probl Gematol Pereliv Krovi 7 (1981) 29-33
44. Weber-Dabrowska B., Mulczyk M., and Gorski A. Bacteriophage therapy for infections in cancer patients. Clin Appl Immunol Rev 1 (2001) 131-134
45. Boratynska M., Szewczyk Z., and Weber-Dabrowska B. Kliniczna ocena bakteriofagow w leczeniu zakazen układu moczowego. Post Med Klin Dosw 3 (1994) 7-11
46. Steininger C. Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system. Clin Microbiol Infect 13 (2007) 953-963
47. Okano M., and Gross T.G. Advanced therapeutic and prophylactic strategies for Epstein-Barr virus infection in immunocompromised patients. Expert Rev Anti Infect Ther 5 (2007) 403-413
48. Leen A.M., and Rooney C.M. Adenovirus as an emerging pathogen in immunocompromised patients. Br J Haematol 128 (2004) 135-144
49. Comoli P., Binggeli S., Ginevri F., and Hirsch H.H. Polyomavirus-associated nephropathy: update on BK virus-specific immunity. Transpl Infect Dis 8 (2006) 86-94
50. Cytomegalovirus. Am J Transpl 2004;4(Suppl 10):51-8.
51. Gandhi M.K., and Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 4 (2004) 725-738
52. LaCasce A.S. Post-transplant lymphoproliferative disorders. Oncologist 11 (2006) 674-680
53. Dabrowska K., Opolski A., Wietrzyk J., Switala-Jelen K., Godlewska J., Boratynski J., et al. Anticancer activity of bacteriophage T4 and its mutant HAP1 in mouse experimental tumour models. Anticancer Res 24 (2004) 3991-3995
54. Dabrowska K., Opolski A., Wietrzyk J., Switała-Jelen K., Boratynski J., Nasulewicz A., et al. Antitumour activity of bacteriophages in murine experimental cancer models caused possibly by inhibition of β3 integrin signalling pathway. Acta Virol 48 (2004) 241-248
55. Dabrowska K., Opolski A., Wietrzyk J., Nevozhay D., Szczaurska K., Switala-Jelen K., et al. Activity of bacteriophages in murine tumor models depends on the router of phage administration. Oncol Res 15 (2005) 183-187
56. Gorski A., Nowaczyk M., Weber-Dabrowska B., Kniotek M., Boratynski J., Ahmed A., et al. New insights into the possible role of bacteriophages in transplantation. Transplant Proc 35 (2003) 2372-2373
57. Gorski A., Kniotek M., Perkowska-Ptasinska A., Mroz A., Przerwa A., Gorczyca W., et al. Bacteriophages and transplantation tolerance. Transpl Proc 38 (2006) 331-333